# A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

> **NCT02340208** · PHASE1,PHASE2 · COMPLETED · sponsor: **Helix BioPharma Corporation** · enrollment: 76 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** L-DOS47

## Key facts

- **NCT ID:** NCT02340208
- **Lead sponsor:** Helix BioPharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2017-08-01
- **Final completion:** 2017-12-20
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340208, "A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02340208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*